Author

Jie Jiang

Harvard UniversityORCID 0000-0003-3795-672XUnclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Jie Jiang3 papers · Beijing Normal University

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Approach:biophysical modeling· 1 Research Focus:cell signaling & trafficking· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Dimitris GazgalisiD· 2 shared Felix H. GottliebiD· 2 shared Michael J. EckiD· 2 shared Pasi Antero JanneiD· 2 shared Adam Stuart KibeliD· 1 shared Anna M. SchmokeriD· 1 shared Anne FassliD· 1 shared Baishan JiangiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Dimitris GazgalisORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyACS Central SciencePeer-reviewedSep 29, 2026

Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775

Zhengnian Li, Jie Jiang, Yaning Wang…·Tinghu Zhang

This paper develops covalent EGFR inhibitors targeting cysteine 775 and 797, showing improved efficacy and resistance delay in osimertinib-resistant models.

DOI 10.1021/acscentsci.6c01219

mouseexperimental assay

𝕏 PostBluesky

BiochemistrybioRxivPreprintDec 17, 2025

RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor

Sayan Chakraborty, Jie Jiang, Javier Viñals…·Michael J. Eck

The paper investigates MEK inhibitor selectivity across RAF isoforms and develops a covalent ARAF-MEK inhibitor with improved potency.

1 citation

proteomicsexperimental assay

𝕏 PostBluesky

Cancer BiologyScience AdvancesPeer-reviewedApr 23, 2025

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer

Fu Gui, Baishan Jiang, Jie Jiang…·Jia Li

This paper introduces BSJ-5-63, a PROTAC that degrades CDK12, CDK7, and CDK9, inducing BRCAness and blocking AR signaling to enhance PARP inhibitor sensitivity in prostate cancer.

21 citationstop 2%

humanexperimental assay

𝕏 PostBluesky